{"pmid":32472706,"title":"The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.","text":["The Long-Standing History of Corynebacterium Parvum, Immunity and Viruses.","We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium Parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenceless situation due to impending CoViD-19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C.parvum protocols. This article is protected by copyright. All rights reserved.","J Med Virol","Palmieri, Beniamino","Vadala, Maria","Roncati, Luca","Garelli, Andrea","Scandone, Francesco","Bondi, Moreno","Cermelli, Claudio","32472706"],"abstract":["We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium Parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenceless situation due to impending CoViD-19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C.parvum protocols. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Palmieri, Beniamino","Vadala, Maria","Roncati, Luca","Garelli, Andrea","Scandone, Francesco","Bondi, Moreno","Cermelli, Claudio"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472706","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26100","keywords":["c.parvum","coronavirus < virus classification","epidemiology","immune responses","immunomodulation < immune responses","innate immunity < immune responses"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668255193479774208,"score":9.490897,"similar":[{"pmid":32441787,"title":"A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19.","text":["A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19.","Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. Studies have shown that coagulation dysfunction is one of the important reason causing death of COVID-19 patients and appeared in many patients. However, cases of COVID-19 with immune thrombocytopenic purpura were very rare. Here, a patient with immune thrombocytopenic purpura in Huoshenshan Hospital (Wuhan, China) was reported, whose laboratory data, clinical treatment and hospital outcome was described in this study. Fortunately, immune thrombocytopenic purpura with COVID-19 of the patient was diagnosed and treated in time and cured eventually. This case illustrates the need to be vigilant for complications associated with COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Yang, Yang","Zhao, Jun","Wu, Jian","Teng, Yi","Xia, Xinyi","32441787"],"abstract":["Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. Studies have shown that coagulation dysfunction is one of the important reason causing death of COVID-19 patients and appeared in many patients. However, cases of COVID-19 with immune thrombocytopenic purpura were very rare. Here, a patient with immune thrombocytopenic purpura in Huoshenshan Hospital (Wuhan, China) was reported, whose laboratory data, clinical treatment and hospital outcome was described in this study. Fortunately, immune thrombocytopenic purpura with COVID-19 of the patient was diagnosed and treated in time and cured eventually. This case illustrates the need to be vigilant for complications associated with COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Yang, Yang","Zhao, Jun","Wu, Jian","Teng, Yi","Xia, Xinyi"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441787","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26051","keywords":["coronavirus < virus classification","disease control","immune responses"],"locations":["Wuhan","China","Huoshenshan Hospital","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1667523504786898945,"score":179.54282},{"pmid":32403318,"title":"Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response.","text":["Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response.","Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus (CoV), is the causative agent of porcine epidemic diarrhea (PED). PED causes lethal watery diarrhea in piglets, which has led to substantial economic losses in many countries and is a great threat to the global swine industry. Interferons (IFNs) are major cytokines involved in host innate immune defense, which induce the expression of a broad range of antiviral effectors that help host to control and antagonize viral infections. PEDV infection does not elicit a robust IFN response, and some of the mechanisms used by the virus to counteract the host innate immune response have been unraveled. PEDV evades the host innate immune response by two main strategies including: (1) encoding IFN antagonists to disrupt innate immune pathway, and (2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provides insights for the better understanding of PEDV-host interactions and developing effective vaccines and antivirals against CoVs.","Pathogens","Li, Shasha","Yang, Jinping","Zhu, Zixiang","Zheng, Haixue","32403318"],"abstract":["Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus (CoV), is the causative agent of porcine epidemic diarrhea (PED). PED causes lethal watery diarrhea in piglets, which has led to substantial economic losses in many countries and is a great threat to the global swine industry. Interferons (IFNs) are major cytokines involved in host innate immune defense, which induce the expression of a broad range of antiviral effectors that help host to control and antagonize viral infections. PEDV infection does not elicit a robust IFN response, and some of the mechanisms used by the virus to counteract the host innate immune response have been unraveled. PEDV evades the host innate immune response by two main strategies including: (1) encoding IFN antagonists to disrupt innate immune pathway, and (2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provides insights for the better understanding of PEDV-host interactions and developing effective vaccines and antivirals against CoVs."],"journal":"Pathogens","authors":["Li, Shasha","Yang, Jinping","Zhu, Zixiang","Zheng, Haixue"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403318","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/pathogens9050367","keywords":["coronavirus","immune evasion","innate immunity","porcine epidemic diarrhea virus","type i ifn"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666802845642391552,"score":178.59622},{"pmid":32464098,"title":"The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?","text":["The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?","The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has had devastating global impacts and will continue to have dramatic effects on public health for years to come. A better understanding of the immune response to SARS-CoV-2 will be critical for the application and development of therapeutics. The degree to which the innate immune response confers protection or induces pathogenesis through a dysregulated immune response remains unclear. In this review, we discuss what is known about the role of the innate immune system during SARS-CoV-2 infection, suggest directions for future studies, and evaluate proposed COVID-19 immunomodulating therapeutics.","Cell Host Microbe","McKechnie, Julia L","Blish, Catherine A","32464098"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has had devastating global impacts and will continue to have dramatic effects on public health for years to come. A better understanding of the immune response to SARS-CoV-2 will be critical for the application and development of therapeutics. The degree to which the innate immune response confers protection or induces pathogenesis through a dysregulated immune response remains unclear. In this review, we discuss what is known about the role of the innate immune system during SARS-CoV-2 infection, suggest directions for future studies, and evaluate proposed COVID-19 immunomodulating therapeutics."],"journal":"Cell Host Microbe","authors":["McKechnie, Julia L","Blish, Catherine A"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464098","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.chom.2020.05.009","keywords":["covid-19","sars-cov-2","complement","cytokines","innate immune response","myeloid cells","natural killer cells"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521216069632,"score":177.06468},{"pmid":32493812,"title":"Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.","text":["Role of Aging and the Immune Response to Respiratory Viral Infections: Potential Implications for COVID-19.","Aging impairs immunity to promote diseases, especially respiratory viral infections. The current COVID-19 pandemic, resulting from SARS-CoV-2, induces acute pneumonia, a phenotype that is alarmingly increased with aging. In this article, we review findings of how aging alters immunity to respiratory viral infections to identify age-impacted pathways common to several viral pathogens, permitting us to speculate about potential mechanisms of age-enhanced mortality to COVID-19. Aging generally leads to exaggerated innate immunity, particularly in the form of elevated neutrophil accumulation across murine and large animal studies of influenza infection. COVID-19 patients who succumb exhibit a 2-fold increase in neutrophilia, suggesting that exaggerated innate immunity contributes to age-enhanced mortality to SARS-CoV-2 infection. Further investigation in relevant experimental models will elucidate the mechanisms by which aging impacts respiratory viral infections, including SARS-CoV-2. Such investigation could identify therapies to reduce the suffering of the population at large, but especially among older people, infected with respiratory viruses.","J Immunol","Chen, Judy","Kelley, William J","Goldstein, Daniel R","32493812"],"abstract":["Aging impairs immunity to promote diseases, especially respiratory viral infections. The current COVID-19 pandemic, resulting from SARS-CoV-2, induces acute pneumonia, a phenotype that is alarmingly increased with aging. In this article, we review findings of how aging alters immunity to respiratory viral infections to identify age-impacted pathways common to several viral pathogens, permitting us to speculate about potential mechanisms of age-enhanced mortality to COVID-19. Aging generally leads to exaggerated innate immunity, particularly in the form of elevated neutrophil accumulation across murine and large animal studies of influenza infection. COVID-19 patients who succumb exhibit a 2-fold increase in neutrophilia, suggesting that exaggerated innate immunity contributes to age-enhanced mortality to SARS-CoV-2 infection. Further investigation in relevant experimental models will elucidate the mechanisms by which aging impacts respiratory viral infections, including SARS-CoV-2. Such investigation could identify therapies to reduce the suffering of the population at large, but especially among older people, infected with respiratory viruses."],"journal":"J Immunol","authors":["Chen, Judy","Kelley, William J","Goldstein, Daniel R"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32493812","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.4049/jimmunol.2000380","locations":["neutrophilia","Aging"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668712823909253120,"score":168.02594},{"pmid":32356908,"title":"Mathematical Modeling of Interaction between Innate and Adaptive Immune Responses in COVID-19 and Implications for Viral Pathogenesis.","text":["Mathematical Modeling of Interaction between Innate and Adaptive Immune Responses in COVID-19 and Implications for Viral Pathogenesis.","We have applied mathematical modeling to investigate the infections of the ongoing COVID-19 pandemic caused by SARS-CoV-2 virus. We first validated our model using the well-studied influenza viruses and then compared the pathogenesis processes between the two viruses. The interaction between host innate and adaptive immune responses was found to be a potential cause for the higher severity and mortality in COVID-19 patients. Specifically the timing mismatch between the two immune responses has a major impact on the disease progression. The adaptive immune response of the COVID-19 patients are more likely to come before the peak of viral load, while the opposite is true for influenza patients. This difference in timing causes delayed depletion of vulnerable epithelial cells in the lungs in COVID-19 patients while enhancing the viral clearance in influenza patients. Stronger adaptive immunity in COVID-19 patients can potentially lead to longer recovery time and more severe secondary complications. Based on our analysis, delaying the onset of adaptive immune responses during early phase of infections may be a potential treatment option for high risk COVID-19 patients. Suppressing the adaptive immune response temporarily and avoiding its interference with the innate immune response may allow the innate immunity to more efficiently clear the virus. This article is protected by copyright. All rights reserved.","J Med Virol","Du, Sean Quan","Yuan, Weiming","32356908"],"abstract":["We have applied mathematical modeling to investigate the infections of the ongoing COVID-19 pandemic caused by SARS-CoV-2 virus. We first validated our model using the well-studied influenza viruses and then compared the pathogenesis processes between the two viruses. The interaction between host innate and adaptive immune responses was found to be a potential cause for the higher severity and mortality in COVID-19 patients. Specifically the timing mismatch between the two immune responses has a major impact on the disease progression. The adaptive immune response of the COVID-19 patients are more likely to come before the peak of viral load, while the opposite is true for influenza patients. This difference in timing causes delayed depletion of vulnerable epithelial cells in the lungs in COVID-19 patients while enhancing the viral clearance in influenza patients. Stronger adaptive immunity in COVID-19 patients can potentially lead to longer recovery time and more severe secondary complications. Based on our analysis, delaying the onset of adaptive immune responses during early phase of infections may be a potential treatment option for high risk COVID-19 patients. Suppressing the adaptive immune response temporarily and avoiding its interference with the innate immune response may allow the innate immunity to more efficiently clear the virus. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Du, Sean Quan","Yuan, Weiming"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356908","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/jmv.25866","keywords":["adaptive immunity","antiviral drugs","covid-19","immunosuppressive drugs","innate immunity","sars-cov-2","target cell-limited model"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495231459329,"score":165.73875}]}